Marquette University

e-Publications@Marquette

Chemistry Faculty Research and Publications

Chemistry, Department of

9-5-2018

Synthesis and Evaluation of 4-Cycloheptylphenols as Selective Estrogen Receptor- β Agonists (SERBAs)

K. L. Iresha Sampathi Perera
Marquette University

Alicia M. Hanson
Concordia University - Wisconsin

Sergey V. Lindeman
Marquette University, sergey.lindeman@marquette.edu

Andrea Imhoff
Concordia University - Wisconsin

Xingyun Lu
Concordia University - Wisconsin

See next page for additional authors

Follow this and additional works at: https://epublications.marquette.edu/chem_fac

Part of the [Chemistry Commons](#)

Recommended Citation

Perera, K. L. Iresha Sampathi; Hanson, Alicia M.; Lindeman, Sergey V.; Imhoff, Andrea; Lu, Xingyun; Sem, Daniel S.; and Donaldson, William A., "Synthesis and Evaluation of 4-Cycloheptylphenols as Selective Estrogen Receptor- β Agonists (SERBAs)" (2018). *Chemistry Faculty Research and Publications*. 987.
https://epublications.marquette.edu/chem_fac/987

Authors

K. L. Iresha Sampathi Perera, Alicia M. Hanson, Sergey V. Lindeman, Andrea Imhoff, Xingyun Lu, Daniel S. Sem, and William A. Donaldson

Marquette University

e-Publications@Marquette

Chemistry Faculty Research and Publications/College of Arts and Sciences

This paper is NOT THE PUBLISHED VERSION; but the author's final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation below.

European Journal of Medicinal Chemistry, Vol. 157 (September 5, 2018): 791-804. [DOI](#). This article is © Elsevier and permission has been granted for this version to appear in [e-Publications@Marquette](#). Elsevier does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

Synthesis and Evaluation of 4-Cycloheptylphenols as Selective Estrogen Receptor- β Agonists (SERBAs)

K. L. Iresha Sampathi Perera

Department of Chemistry, Marquette University, Milwaukee, WI

Alicia M. Hanson

School of Pharmacy, Center for Structure-based Drug Design and Development, Concordia University Wisconsin, Mequon, WI

Sergey Lindeman

Department of Chemistry, Marquette University, Milwaukee, WI

Andrea Imhoff

School of Pharmacy, Center for Structure-based Drug Design and Development, Concordia University Wisconsin, Mequon, WI

Xingyun Lu

School of Pharmacy, Center for Structure-based Drug Design and Development, Concordia University Wisconsin, Mequon, WI

Daniel S. Sem

School of Pharmacy, Center for Structure-based Drug Design and Development, Concordia University Wisconsin, Mequon, WI

William A. Donaldson

Department of Chemistry, Marquette University, Milwaukee, WI

Abstract

A short and efficient route to 4-(4-hydroxyphenyl)cycloheptanemethanol was developed, which resulted in the preparation of a mixture of 4 [stereoisomers](#). The stereoisomers were separated by preparative HPLC, and two of the stereoisomers identified by [X-ray crystallography](#). The stereoisomers, as well as a small family of 4-cycloheptylphenol derivatives, were evaluated as [estrogen](#) receptor-beta [agonists](#). The [lead compound](#), 4-(4-hydroxyphenyl)cycloheptanemethanol was selective for activating ER relative to seven other [nuclear hormone receptors](#), with 300-fold selectivity for the β over α isoform and with EC₅₀ of 30–50 nM in cell-based and direct binding assays.

Graphical abstract

Keywords

SERBA, Estrogen receptor agonist, Drug development, Cancer

1. Introduction

[Estrogens](#) play an important role in the growth, development and maintenance of a variety of tissues which is mainly mediated by the estrogen receptor (ER), a ligand-activated [nuclear receptor](#) transcription factor. There are two main isoforms of the estrogen nuclear receptor, ER α and ER β , which are found to diverge with respect to their transcriptional activities and [tissue distribution](#). Upon binding of [estradiol](#), ER activation can exert beneficial effects for the prostate, colon, and brain. Indeed, ER β itself is a target for agonist-based drug leads to treat a wide range of indications, including depression [1], anxiety [2], [dementia](#) [3], and even cancer [4]. In contrast, ER α activity can present risks for cancer [5]. Thus, there is a therapeutic need for potent and selective ER β [agonists](#) [6]. These differential effects have prompted researchers to search for novel ER β selective ligand agonists as therapeutic agents ([Fig. 1](#)).

Fig. 1. Achiral and optically active [estrogen](#) receptor- β selective ligands. (ref. [1], [9], [10], [11], [12], [13]).

Although the [ligand binding](#) domains (LBDs) of ER α and ER β share less than 60% [sequence homology](#), the ligand binding pockets (LBP) of the two subtypes have only minor differences in structure and composition [7]. The two LBPs are composed of 23 [amino acid residues](#), 21 of which are conserved and only two of which are variant. The residues Leu384 and Met421 in ER α are replaced with Met336 and Ile373 in ER β respectively. Furthermore, the interchanged Leu384/Met336 residues are positioned above the B- and C-rings of estradiol whereas the interchanged Met421/Ile373 residues are positioned below the estradiol D-ring within the LBP. These minute alterations in [amino acid sequence](#) plus other small variations in [tertiary structure](#) make the ER β LBP smaller in volume (282 Å³) in comparison to the LBP of ER α (379 Å³) [8].

Several achiral and chiral ER β selective agonist compounds have been reported (Fig. 1) [6](d), [9], [10], [11], [12], [13]. For chiral compounds, the difference in ER selectivity for one [enantiomer](#) was generally less than 2-fold.

We have previously reported the synthesis of *cis*-4-(4-hydroxyphenyl)cycloheptanemethanol ($\pm$)-**2** from [furan](#) (10 steps, 1.9% overall yield, [Scheme 1](#)) [14,15]. Evaluation of ($\pm$)-**2** in cell-based assays revealed a potent and highly selective ER β agonist. We herein report alternative syntheses of **2**, which result in the preparation of a [racemic mixture](#) of four [stereoisomers](#), the separation of these stereoisomers and structural characterization of two of the enantiomeric structures, and the evaluation of the four stereoisomers as ER β ligands, and promising ER β agonist therapeutic lead molecules.

Scheme 1. Prior synthesis of *cis*-4-(4-hydroxyphenyl)cycloheptanemethanol (refs. [14], [15]).

2. Results and discussion

2.1. Chemistry

Several routes to 4-(4-hydroxyphenyl)cycloheptanemethanol were developed ([Scheme 2](#)). Addition of the [Grignard reagent](#) prepared from 4-bromo-1-butene with methyl [4-methoxybenzoate](#) **3a** gave the [tertiary alcohol](#) **4a**. [Ring closing metathesis](#) of **4a** with 4% Grubbs' 1st generation catalyst afforded cycloheptenol **5a**, which underwent ionic reduction to generate the [cycloheptene](#) **6a**. Hydroboration-oxidation of **6a**, followed by [oxidation](#) with [Dess-Martin periodinane](#) gave the known [16] cycloheptanone ($\pm$)-**8a**. Wittig [olefination](#) of **8a**, followed by hydroboration-oxidation afforded the methyl [ether](#) **10a**. Cleavage of the methyl ether using BBr₃ proceeded in a disappointing 30% yield to give a ca. 1:1 mixture of ($\pm$)-*cis*- and ($\pm$)-*trans*-4-(4-hydroxyphenyl)cycloheptanemethanol (**ISP163**). This 8-step route proceeded in 3.7% overall yield.

Scheme 2. Synthesis of mixture of *cis*- and *trans*-4-(4-hydroxyphenyl)cycloheptanemethanol. Reagents: a, Mg, BrCH₂CH₂CH = CH₂, THF (**4a**, 85%; **4b**, 80%); b, 4% PhCH = RuCl₂(PCy₃)₂, CH₂Cl₂/Δ (**5a**, 75%; **5b**, 86%); c, Et₃SiH, TFA, CH₂Cl₂ (**6a**, 90%; **6b**, 60% + 16% **6c**); d, TBSCl, [imidazole](#) (70%); e, (i) BH₃-THF, (ii) 30% H₂O₂, 3 *N* NaOH (**7a**, 93%; **7b**, 93%); f, [Dess Martin periodinane](#) (**8a**, 55%; **8b**, 72%); g, *n*-BuLi, Ph₃PCH₃⁺ Br⁻ (**9a**, 78%; **9b**, 57%); h, (i) BH₃-THF, (ii) 30% H₂O₂, 3 *N* NaOH (48%); i, (i) BH₃-THF, (ii) 30% H₂O₂, 1 *N* NaOH (66%); j, BBr₃ (30%); k, TBAF, THF (88%); l, N₂CHCO₂Et/BF₃-Et₂O (81%); m, LiCl/H₂O/DMSO/Δ (73%).

Due to the low yield of the BBr₃ cleavage, an alternate phenolic protecting group was explored. Beginning with methyl 4-(4-*t*-butyldimethylsilyloxy)benzoate **3b**, the above sequence of reactions gave intermediates **4b-10b**, which deserve a few comments. The ionic reduction of **5b** gave a separable mixture of **6b** (60%) along with some of the unprotected [phenol](#) **6c** (16%). This phenol could be recycled to **6b** by TBS protection.

Furthermore, [hydroboration](#) of **9b**, followed by oxidative work-up with H₂O₂/3 *N* NaOH proceeded with concomitant cleavage of the [silyl ether](#) to generate **ISP-163** (40%). Improved yield was effected by changing the work-up to 1 *N* NaOH followed by TBAF deprotection. This 8-step route proceeded to generate **ISP-163** in 9.2% overall yield.

Finally, a third shortened route was developed. [Ring expansion](#) of 4-(4-*t*-butyldimethylsilyloxyphenyl)cyclohexanone (**11**) with [ethyl](#) diazoacetate [[16](#)] gave the α-ethoxycarbonylcycloheptanone **12**, which upon decarboethoxylation gave (±)-**8b** (2 steps, 59%). This alternative 5-step route gave **ISP-163** in 19.6% overall yield.

[Demethylation](#) of **7a** and **8a** gave the cycloheptanol **ISP58** and cycloheptanone **ISP242** respectively ([Scheme 3](#)). Reaction of **ISP242** with [hydroxylamine](#) gave the [oxime](#) **ISP166** as a mixture of *E*- and *Z*-stereoisomers. [Horner-Emmons](#) olefination of **8a**, followed by DIBAL reduction, [olefin](#) reduction and cleavage of the methyl ether gave the hydroxyethyl analog **ISP248**, as a mixture of *cis*- and *trans*-[stereoisomers](#). Finally, oxidative [cyclization](#) of **ISP163** with DDQ gave the 2-oxabicyclo[3.2.2]nonane **ISP360**.

Scheme 3. Reagents: a, 45% HBr/ Δ (82%); b, NaH, MeO₂CCH₂P(O) (OMe)₂ (30%); c, LiAlH₄ (43%); d, H₂, Pd/C; e, BBr₃/CH₂Cl₂ (10% over two steps); f, H₂NOH-HCl/NaHCO₃/EtOH (50%); g, DDQ/CH₂Cl₂ (66%); h, BBr₃/CH₂Cl₂ (86%).

While the mixture of *cis*- and *trans*-isomers 4-(4-hydroxyphenyl)cycloheptanemethanol (ISP163) proved inseparable in our hands by SiO₂ [column chromatography](#), the four stereoisomers could be separated by [chiral HPLC](#). A preparative separation was contracted with Phenomenex (Torrance, CA). Initial [analytical method](#) development by Phenomenex revealed that a Lux Cellulose-3 5um column and isocratic [mobile phase](#) of ethanol: [2-propanol](#): [hexanes](#) (4.33: 8.66: 87) was optimum, with detection at 280 nM. The isolation process utilized a 250 × 30 mm preparative column and the aforementioned solvent system. This method produced a 12 min HPLC run with the first desired peak eluting just before 8 min. Since these conditions were isocratic, stacked injections were implemented to accelerate the process. In this regard, subsequent injections were made 6 min after the previous injection with the products from the first injection collected shortly after the second injection was made. Analytical QC chromatograms confirmed separation of the stereoisomers and indicated that each fraction was >94% of the [enantiomeric excess](#) ([Fig. 2](#)).

Fig. 2. Analytical QC chromatograms of four peaks of ISP163.

The *cis*-stereochemistry was assigned to the 3rd and 4th fractions (**ISP163p3** and **ISP163p4**) by comparison of their ^{13}C NMR spectra with that for $(\pm)$ -2 [14]; and thus the 1st and 2nd fractions (**ISP163p1** and **ISP163p2**) were assigned the *trans*-stereochemistry in order to be unique. These assignments were further corroborated by [single crystal X-ray diffraction](#) analysis of the 2nd, 3rd, and 4th fractions [17]. In addition, the [crystal structures](#) of **ISP163p3** (Fig. 3) and **ISP163p4** revealed the *absolute* configuration of these [isomers](#) to be 1*S*, 4*R* and 1*R*,4*S*-(4-hydroxyphenyl)cycloheptanemethanol respectively. Although the crystal structure of **ISP163p2** corroborated its *trans*-stereochemistry, it was not possible to determine the [absolute configuration](#) from these [crystals](#).

Fig. 3. ORTEP of 1*S*,4*R*-(4-hydroxyphenyl)cycloheptanemethanol **ISP163p3**.

2.2. Determining ISP163 extinction coefficient and isomer stock concentrations

The amount of powder of the **ISP163** isomers generated by [chiral chromatography](#) was often not sufficient to accurately weigh a mass for creation of [DMSO](#) stocks used in the [ligand binding](#) assays. Therefore, solid samples were dissolved in DMSO and the concentration of each stock was determined spectrophotometrically. First, the absorbance spectra for solutions of **ISP163** were obtained (Fig. 4a) and the λ_{max} peak was determined to occur at 276 nm. Then, the extinction coefficient of **ISP163** was determined to be $1892 \text{ M}^{-1}\text{cm}^{-1}$ from triplicate linear regressions of the peak absorbance (Fig. 4b). Two [dilutions](#) of **ISP163** isomer stocks were used to calculate the concentration of the stock. The average of the two calculated concentrations was determined to be the concentration of the stock solution.

Fig. 4. **Determining ISP163 Extinction Coefficient.** (a) Representative absorbance scans of **ISP163** in 20 mM [potassium phosphate](#) buffer, pH 7.5 and 0.4% [DMSO](#). (b) Plot of the absorbance value at 276 nm for each concentration of **ISP163** for 3 replicate experiments. Linear regression lines were forced through 0,0. The extinction coefficient of **ISP163** was determined to be $1892 \text{ M}^{-1} \text{ cm}^{-1}$ by averaging the slope of the 3 linear regression lines.

2.3. Biological activity evaluation

2.3.1. Binding, coactivator, and cell-based assays

Compounds were initially screened in the TR-FRET binding assay which detects binding of the compound to the [ligand binding domain](#) (LBD) of ER β via displacement of a fluorescent [estrogen](#). All compounds synthesized were tested in a dose-response curve ([Fig. 5a,c](#)) and EC₅₀ values are summarized in [Table 1](#). The most potent compounds were **ISP58**, **ISP163**, and **ISP248** with EC₅₀s < 75 nM. Secondary assays in a cell-based transcription assay with full-length ER β and ER α revealed **ISP163** to be the most potent (ER β EC₅₀ 33 $\pm$ 5 nM) and most selective compound (318-fold selective for ER β over ER α). To see if the selectivity for ER β observed in the cell-based transcription assays was due to differential binding to the ERs, we conducted TR-FRET binding assays with the ER α – LBD. Surprisingly, we observed only modest 1.9-fold selectivity for binding to the LBD of ER β over ER α for **ISP163** ([Fig. 5b](#)). Since **ISP163** is a mixture of isomers, we tested the 4 separated isomers in the TR-FRET binding displacement assays ([Fig. 5c and d](#) replicate assays in [Figs. S1 and S2](#)) and in the cell-based full-length ER transcription assays ([Table 1](#) and [Fig. 6](#)). In the TR-FRET binding assay, **ISP163p1** and **ISP163p2** (i.e. trans cycloheptane) were found to be slightly more potent than the other two isomers, and more potent than the mixture. Surprisingly, in the cell-based assay, the ER β [agonist](#) potency of the mixture of stereoisomers (**ISP163**) is actually slightly greater than any of the individual stereoisomers. The potency of three of these stereoisomers (**ISP163p1**, **ISP163p2** and **ISP163p4**), are relatively close in value to that for the mixture with only **ISP163p3**, ca. 4x less potent than the mixture. One possible rationale is that the individual stereoisomers exhibit a [synergism](#) in terms of their activation in the context of the cell-based assay [\[18\]](#). In the cell-based transcription assay, ligand binding to ER β receptor is followed by [dimerization](#), and that the [dimer](#) binds to DNA promoting transcription. It is possible that synergistic binding of two different compounds in the mixture via this mechanism could produce greater transcriptional activity compared to an ER β [homodimer](#). But, further studies would be needed to prove this mechanism and it is noted that the difference in affinity between the isomers is relatively modest (2–4 fold). In summary, there do not appear to be significant difference in [binding affinity](#) for the four isomers, consistent with docking studies ([Fig. 9](#)).

Fig. 5. TR-FRET [Estrogen Receptor Binding](#). (a) Binding assay for the [ligand binding domain](#) (LBD) of ER β (See [Table 1](#) for EC₅₀ values). (b) **ISP163** binding to the LBDs of ER β (EC₅₀ = 53 $\pm$ 15 nM) and ER α (EC₅₀ = 99 $\pm$ 24 nM) showing a 1.9-fold selectivity for ER β over ER α . (c) Binding of **ISP163** [isomers](#) to the LBD of ER β and (d) ER α (EC₅₀ values in [Table 1](#).).

Table 1. Biological evaluation of compounds in TR-FRET Binding and Cell-based Transcription Assays. EC₅₀ values are in nM.

Compound	TR-FRET ligand displacement assay			Cell-based transcription assay				
	ERβ EC ₅₀	ERα EC ₅₀	ERβ/ERα selectivity	ERβ agonism EC ₅₀	ERβ antagonism EC ₅₀	ERα agonism EC ₅₀	ERα antagonism EC ₅₀	ERβ/ERα agonist selectivity
E2	0.25 ± 0.06	0.26 ± 0.03	1.0	0.022 ± 0.005	ND	0.31 ± 0.03	ND	14
ISP163	53 ± 15	99 ± 24	1.9	33 ± 5	>100,000	10,500 ± 200	>10,000	318
ISP163p1	18 ± 6	96 ± 18	5.3	50 ± 2	>35,600	>3000	>35,600	>60
ISP163p2	28 ± 19	61 ± 13	2.2	48 ± 4	>23,200	>10,000	>10,000	>208
ISP163p3	99 ± 56	221 ± 34	2.2	121 ± 12	>10,000	>10,000	>10,000	>83
ISP163p4	66 ± 20	199 ± 40	3.0	51 ± 8	>11,600	>11,600	>11,600	>227
ISP248	75 ± 19	ND	—	139 ± 15	>10,000	>10,000	>10,000	>72
ISP58	42 ± 18	ND	—	362 ± 30	>10,000	>10,000	>10,000	>27
ISP166	600 ± 99	ND	—	>800	>10,000	>10,000	>10,000	>12
ISP360	509 ± 163	ND	—	ND	ND	ND	ND	—
ISP242	435 ± 118	ND	—	ND	ND	ND	ND	—

Fig. 6. Cell-based assays for ISP163p4. Cell-based full-length ER transcription assays for (a) [agonist](#) activity and (b) [antagonist](#) activity. ISP163p4 shows >227-fold agonist selectivity for ERβ over ERα in this assay (ERβ EC₅₀ = 51 ± 8 nM, ERα EC₅₀ > 11,600 nM) and no antagonist activity.

To test the selectivity of ISP163p4 for estrogen receptors compared to other [nuclear hormone receptors](#), Thermo Fisher Scientific SelectScreen services were utilized. ISP163p4 was tested against 9 nuclear hormone receptors at 3 different concentrations (Fig. 7a) and only showed activity with the estrogen receptors at any of the concentrations. This assay involves a chimeric ER-LBD tethered to the DNA-binding Domain (DBD) of GAL4. Ligand binding initiates transcription of the [beta-lactamase](#) gene. Addition of a beta-lactamase substrate to cells allows for quantification of the [transcriptional activation](#). Dose-response curves in this assay, which uses a chimeric receptor, showed no selectivity for ISP163p4 activating ERβ over ERα (Fig. 7b).

Fig. 7. GeneBLazer™ Nuclear Hormone Assay for ISP163p4. (a) [Agonist](#) activity as measured in the cell-based GeneBLazer™ [transcription activation](#) assay using chimeric [nuclear hormone receptors](#) (NRs) comprised of the receptor [ligand-binding domain](#) tethered to the DNA-binding domain of GAL4. Nine different NRs were

tested: [Androgen Receptor](#) (AR), Glucocorticoid Receptor (GR), [Mineralocorticoid Receptor](#) (MR), [Peroxisome Proliferator-Activated Receptor](#) (PPAR δ), [Progesterone Receptor](#) (PR), [Thyroid Hormone Receptor](#) (TR β), Vitamin D Receptor (VDR). (b) GeneBLAzer™ agonist-activity dose-response assays for ER β and ER α (open symbols) showing no selectivity (ER β EC₅₀ = 735 $\pm$ 94 nM, ER α EC₅₀ = 825 $\pm$ 82 nM). For comparison, data from panel (a) are included (closed symbols).

We hypothesize that the difference in specificity in the cell-based transcription assays (that uses native full-length ER) compared with the other assays (that rely on isolated LBD or chimeric ER) has to do with the ability of the compound to bind to the native estrogen receptor and – as a result of binding – cause the correct conformational change that allows downstream coactivator proteins to bind. To test this hypothesis, we measured **ISP163p4** binding and selectivity in the LanthaScreen TR-FRET Coactivator Assay (Thermo Fisher Scientific). In this assay, the ER-LBD undergoes a conformational change upon ligand binding that allows a fluorescent coactivator peptide to bind in the adjacent ER coactivator pocket. The peptide in this assay is derived from the PPAR γ coactivator protein 1a. In this assay, **ISP163p4** now shows 4.7-fold selectivity for ER β (EC₅₀ = 566 $\pm$ 57 nM) over ER α (EC₅₀ = 2660 $\pm$ 479 nM) ([Fig. 8](#)). This is consistent with **ISP163p4** selectivity being a function of more than just affinity for the LBD, as hypothesized.

Fig. 8. ISP163p4 Coactivator Binding Assay for Specificity. This assay measures the binding of a coactivator peptide derived from the PPAR γ coactivator protein 1a to the ER β or ER α LBD. [Agonist](#) binding (**ISP163p4** here) induces a conformational change in the LBD allowing the peptide to bind. Dose-response curves in this assay give an EC₅₀ of 566 $\pm$ 57 nM for ER β and 2660 $\pm$ 479 nM for ER α , showing 4.7-fold selectivity for ER β .

Fig. 9. Docking of ISP163 [Isomers](#) into ER β . All four isomers of 4-(4-hydroxyphenyl)cycloheptanemethanol **ISP163** docked into the binding pocket of [agonist](#) mode human ER β (pdb code [2jj3](#)) [[19](#)]: (a) (4R, 1R) [stereoisomer](#), (b) (4S, 1S) stereoisomer, (c) (4R, 1S) stereoisomer **ISP163p3**, and (d)

(4S,1R) stereoisomer **ISP163p4**. The active site, with surrounding helices rendered as ribbons, is shown in panel (e) for the **ISP163p4**/ER β complex. All low energy docking poses are shown overlaid for **ISP163** isomers in panel (f), illustrating that while there is variability in orientation of the cycloheptyl ring, the [hydroxyl group](#) location (hydrogen-bonded to His524) is constant.

The selectivity of **ISP163** was further assessed by screening against common central nervous system (CNS) receptors by the NIMH Psychoactive [Drug Screening](#) Program (PDSP) at the University of North Carolina at Chapel Hill. **ISP163** was also screened against the hERG heart [potassium ion channel](#) by the PDSP. No significant [inhibition](#) was observed for any CNS receptors or hERG ([Table 2](#)).

Table 2. PDSP screening of **ISP163**.

Receptor	% Inhibition at 10 μ M
Serotonin	
5-HT _{1A}	14.6
5-HT _{1D}	25.3
5-HT _{2B}	-7.3
5-HT ₆	19.0
5-HT ₇	-8.5
Adrenergic	
α_{1A}	-3.7
α_{1B}	-4.9
α_{1D}	-16.7
β_1	-4.8
β_3	16.0
Histamine	
H ₂	2.7
H ₄	-0.1
Ion Channel	
hERG	-1.7
Other	
σ_1	17.1
σ_2	31.9

2.3.2. In-silico comparison of ISP163 isomer binding

While **ISP163** is the most potent and selective cycloheptylphenol ER β agonist we have identified, it has four stereoisomers ([Fig. 2](#)), each of which could in principle have different activities. **ISP161p1** appears to have only slightly higher affinity ($EC_{50} = 18$ nM) than the other 3 isomers, in terms of binding to the ER β LBD; but, in the biologically more relevant cell-based assay, they are all of similar potency and selectivity ([Table 1](#)). To assess why the isomers have similar affinities, all were docked into the ER β active site. All bound in similar orientations, with some conformational variability observed only in the cycloheptyl ring; but in all cases, the positioning of the two [hydroxyl groups](#) was similar in the active site ([Fig. 9f](#)). Docking energies were also similar for the four isomers: **ISP163p1** (-8.5 kcal/mol), **ISP163p2** (-8.3 kcal/mol), **ISP163p3** (-8.3 kcal/mol), and **ISP163p4** (-8.1 kcal/mol).

2.3.3. Assessment of physico/physiochemical properties - CYP450 binding and nephelometry

In addition to the lack of activity against the seven nuclear hormone receptors ([Fig. 7](#)), initial assessment of physicochemical properties of **ISP163** was made by measuring [cytochrome P450](#) binding, in assays with the four major cytochrome P450 enzymes. Significant inhibition of [CYP2C9](#) was observed ($IC_{50} = 2.7 \pm 0.3$ μ M), moderate

inhibition of [CYP3A4](#) was observed ($IC_{50} = 33 \pm 3 \mu M$), and no significant inhibition was observed for [CYP2D6](#) or [CYP1A2](#) (Fig. S3). [Solubility](#) of **ISP163** is adequate, based on [nephelometry](#) where no significant aggregation was observed when tested up to 250 μM (Fig. S4).

2.3.4. Breast cancer proliferation assays

While estrogen agonists have a number of therapeutic applications, they can be pro-carcinogenic by causing proliferation of breast cancer cells [5,6,20]; although, the opposite effect has been reported for $ER\beta$ agonists [2]. For this reason, the impact of **ISP163** on the proliferation of human breast cancer cells was assessed by conducting [MTT assays](#) with MCF-7 cells. Significant [cell proliferation](#) was observed in cells treated with 0.01 μM E2 ($n = 3$; $p \leq 0.01$) compared to untreated controls (Fig. 10), consistent with a mild pro-carcinogenic effect due to its $ER\alpha$ agonist activity. In contrast, no significant changes in growth of MCF-7 cells was observed when cells were treated with any concentration of **ISP163** compared to untreated controls; and, proliferation was significantly lower compared to cells treated with 0.01 μM E2 ($n = 3$; $p \leq 0.04$ for all concentrations).

Fig. 10. [MTT Assays](#) with **ISP163**. MCF-7 cells were grown in 96-well plates for 24 h after which treatment was applied. Cells were incubated an additional 24 h after which the MTT assay was done. A standard growth curve was used to convert absorbance values to cell number. * indicates significant [cell proliferation](#) compared to untreated controls and to each concentration of **ISP163**. Results with 1, 0.1, and 0.001 μM **ISP163** are not shown because results were similar to 10 and 0.01 μM . Note the vertical axis break.

3. Conclusion

The results of the present study demonstrate that **ISP163**, 4-(4-hydroxyphenyl)cycloheptanemethanol, is selective for $ER\beta$, in cell-based assays, and that there are negligible differences in potency and selectivity among the four [stereoisomers](#). While **ISP163** does not cause MCF-7 [cell proliferation](#), shows no significant aggregation up to 250 μM , and does not inhibit [CYP2D6](#) or [CYP1A2](#), it significantly inhibits [CYP2C9](#) and moderately inhibits [CYP3A4](#). If **ISP163** is to be developed as a drug lead, the binding to CYP2C9 will need to be addressed.

4. Experimental

4.1. Chemistry

4.1.1. General experimental

All reactions involving moisture or air sensitive reagents were carried out under a [nitrogen](#) atmosphere in oven-dried glassware with anhydrous solvents. THF and [ether](#) were distilled from sodium/benzophenone. [Purifications](#) by chromatography were carried out using flash [silica gel](#) (32–63 μ). [NMR spectra](#) were recorded on either a Varian Mercury+ 300 MHz or a Varian UnityInova 400 MHz instrument. $CDCl_3$, CD_3OD and $DMSO-d_6$ was purchased from Cambridge Isotope Laboratories. 1H NMR spectra were calibrated to

7.27 ppm for residual CHCl_3 or 3.31 ppm for CD_2HOD . ^{13}C NMR spectra were calibrated from the central peak at 77.23 ppm for CDCl_3 or 49.15 ppm for CD_3OD . [Coupling constants](#) are reported in Hz. [Elemental](#) analyses were obtained from Midwest Microlabs, Ltd., Indianapolis, IN, and [high-resolution mass spectra](#) were obtained from the COSMIC lab at Old Dominion University.

4.1.2. 5-(4-Methoxyphenyl)-1, 8-nonadien-5-ol **4a**

To a flame dried three-necked flask fitted with a condenser and addition funnel was charged with [magnesium](#) turnings (3.654 g, 152.1 mmol) and dry THF (30 mL) while maintaining the system under N_2 . The addition funnel was loaded with a solution of 4-bromo-1-butene (7.72 mL, 76.1 mmol) in THF (20 mL), and a small amount of the bromobutene solution (2 mL) was added slowly to the magnesium turnings, and the contents were heated to reflux. Once the Grignard formation had started, the heat was removed and the remaining [bromide](#) solution was added dropwise maintaining a gentle reflux. The mixture was stirred until most of the magnesium had reacted. A solution of methyl [4-methoxybenzoate](#) **3a** (2.528 g, 15.20 mmol) in THF (30 mL) was loaded into the addition funnel and added dropwise over 30 min. After stirring overnight at room temperature, a saturated solution of NH_4Cl (30 mL) was added to quench the reaction. The resultant [emulsion](#) was stirred for 2 h and the solution was extracted several times with ether. The combined organic layers were washed with water, followed by brine, dried (MgSO_4) and concentrated to give alcohol **4a** as a yellow oil (3.182 g, 85%). ^1H NMR (400 MHz, CDCl_3) δ 7.29 and 6.88 (AA'BB', $J_{\text{AB}} = 8.9$ Hz, 4H, ArH), 5.84–5.73 (m, 2H, $\text{CH}=\text{CH}_2$), 4.98–4.88 (m, 4H, $\text{CH}=\text{CH}_2$), 3.81 (s, 3H, OMe), 1.96–1.84 (m, 8H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.2, 139.0, 137.9, 126.6, 114.7, 113.6, 77.0, 55.4, 42.3, 28.2 ppm. HRMS (FAB): $\text{M}_2 + \text{Na}^+$, found 515.3130. $(\text{C}_{16}\text{H}_{22}\text{O}_2)_2\text{Na}$ requires 515.3132.

4.1.3. 5-(4-*t*-Butyldimethylsilyloxyphenyl)nona-1,8-dien-5-ol **4b**

The reaction of methyl 4-*t*-butyldimethylsilyloxybenzoate (5.000 g, 0.0188 mmol) with the [Grignard reagent](#) generated from 4-bromo-1-butene (11.5 mL, 0.113 mol) was carried out in a fashion similar to the preparation of **4a**, to give **4b** as a colorless oil (5.208 g, 80%). ^1H NMR (400 MHz, CDCl_3) δ 7.23 and 6.82 (AA'BB', $J_{\text{AB}} = 8.6$ Hz, 4H, ArH), 5.85–5.73 (m, 2H, $\text{CH}=\text{CH}_2$), 5.01–4.86 (m, 4H, $\text{CH}=\text{CH}_2$), 2.13–1.80 (m, 9H), 1.01 (s, 9H, *t*-Bu), 0.22 (s, 6H, SiMe_2); ^{13}C NMR (100 MHz, CDCl_3) δ 154.2, 139.1, 138.5, 126.5, 119.7, 114.7, 77.0, 42.2, 28.2, 25.8, 18.3, –4.2 ppm.

4.1.4. 1-(4-Methoxyphenyl)-4-cyclohepten-1-ol **5a**

To a solution of **4a** (1.015 g, 4.126 mmol) in dry CH_2Cl_2 (415 mL, 0.01 M) at 40 °C was slowly added via syringe pump over a 10 h period, a solution of [Grubbs](#) I catalyst (0.136 g, 0.165 mmol, 4%) in CH_2Cl_2 . The mixture was heated for an additional 12–18 h. After cooling to room temperature, the mixture was quenched with [DMSO](#) (50 eq, 0.600 mL) and stirred for another 12 h. The mixture was concentrated and the residue was purified by [column chromatography](#) (SiO_2 , hexanes–diethyl ether = 4:1) to give **5a** (0.675 g, 75%) as a green oil. ^1H NMR (400 MHz, CDCl_3) δ 7.43 and 6.87 (AA'BB', $J_{\text{AB}} = 9.0$ Hz, 4H, ArH), 5.86–5.83 (m, 2H, $\text{CH}=\text{CH}$), 3.80 (s, 3H, OMe), 2.55–2.44 (m, 2H), 2.10–1.97 (m, 4H), 1.90–1.82 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 158.4, 142.4, 132.12, 125.9, 113.6, 76.7, 55.4, 40.2, 23.2 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 241.1202. $\text{C}_{14}\text{H}_{18}\text{O}_2\text{Na}$ requires 241.1199.

4.1.5. 1-(4-((*tert*-Butyldimethylsilyl)oxy)phenyl)cyclohept-4-en-1-ol **5b**

The [ring closing metathesis](#) of **4b** (0.313 g, 0.903 mmol) in dry CH_2Cl_2 (100 mL, 0.01 M) with Grubbs I catalyst (0.029 g, 0.032 mmol, 4%) was carried out in a fashion similar to the preparation of **5a**. Purification of the residue by column chromatography (SiO_2 , hexanes–diethyl ether = 4:1) gave **5b** (0.247 g, 86%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.35 and 6.79 (AA'BB', $J_{\text{AB}} = 8.7$ Hz, 4H, ArH), 5.86–5.79 (m, 2H, $\text{CH}=\text{CH}$), 2.54–2.43 (m, 2H), 2.10–1.94 (m, 4H), 1.90–1.82 (m, 2H), 1.73 (s, 1H), 0.99 (s, 9H, *t*-Bu), 0.20 (s, 6H, SiMe_2); ^{13}C NMR (100 MHz, CDCl_3) δ 154.5, 142.9, 132.3, 125.9, 119.7, 76.7, 40.3, 25.8, 23.2, 18.3, –4.2 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 325.1959. $\text{C}_{19}\text{H}_{30}\text{OSiNa}$ requires 325.1958.

4.1.6. 5-(4-Methoxyphenyl)cycloheptene 6a

To a solution of **5a** (1.720 g, 7.880 mmol) in dry CH_2Cl_2 (50 mL) was added triethylsilane (1.4 mL, 0.22 mmol), followed by TFA (6.2 mL, 79 mmol). The mixture was stirred at room temperature for 48 h while monitoring by TLC. After complete disappearance of the starting material, the solution was concentrated to a [bilayer](#) oil and purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 50:50) to give **6a** as a brown oil (1.433 g, 90%). ^1H NMR (400 MHz, CDCl_3) δ 7.11 and 6.84 (AA'BB', $J_{\text{AB}} = 8.6$ Hz, 4H, ArH), 5.91–5.87 (m, 2H, $\text{CH}=\text{CH}$), 3.79 (s, 3H, OMe), 2.69 (tt, $J = 11.3, 3.2$ Hz, 1H, H^5), 2.35–2.25 (m, 2H), 2.23–2.13 (m, 2H), 1.91–1.83 (m, 2H), 1.54–1.43 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.8, 141.7, 132.7, 127.7, 113.9, 55.4, 49.6, 35.1, 28.1 ppm.

4.1.7. 5-(4-*t*-Butyldimethylsilyloxyphenyl)cycloheptene 6b

The ionic reduction of **5b** (1.601 g, 5.026 mmol) in anhydrous CH_2Cl_2 (20 mL) with triethylsilane (0.8 mL, 1.02 mmol) and TFA (4.0 mL, 20 mmol) was carried out in a fashion similar to preparation of **6a**. Purification of the residue by column chromatography (SiO_2 , [hexanes](#) = 100%) gave **6b** (0.906 g, 60%) as a light yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.05 and 6.78 (AA'BB', $J_{\text{AB}} = 8.7$ Hz, 4H, ArH), 5.92–5.89 (m, 2H, $\text{CH}=\text{CH}$), 2.69 (tt, $J = 11.2, 3.2$ Hz, 1H, H^5), 2.36–2.27 (m, 2H), 2.24–2.14 (m, 2H), 1.93–1.85 (m, 2H), 1.55–1.44 (m, 2H), 1.01 (s, 9H, *t*-Bu), 0.22 (s, 6H, SiMe_2); ^{13}C NMR (100 MHz, CDCl_3) δ 153.7, 142.2, 132.7, 127.6, 120.0, 49.7, 35.1, 28.1, 25.9, 18.4, –4.2 ppm.

4.1.8. 4-(4-Methoxyphenyl)cycloheptanol 7a

To a solution of **6a** (1.24 g, 5.67 mmol) in freshly distilled THF (25 mL) at 0 °C under N_2 , was added dropwise a solution of BH_3 -THF (1 [M](#) in THF, 11.3 mL, 11.3 mmol). The solution was warmed to room temperature and stirred for 20 h. The reaction mixture was cooled to 0 °C, and water (440 mL) was slowly added followed by 30% H_2O_2 (8.50 mL) and 1 [N](#) NaOH (14.5 mL). The resulting mixture was stirred at room temperature for 30 min, extracted several times with [ethyl acetate](#), and the combined extracts concentrated. The residue was purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 60:40) to give **7a** (1.150 g, 93%) as a yellow oil. This product was determined to be a mixture of *cis*- and *trans*-stereoisomers by [NMR spectroscopy](#). ^1H NMR (400 MHz, CDCl_3) δ 7.11 and 7.09 (2 x d, $J = 8.3$ Hz, 2H total, ArH), 6.83 (d, $J = 8.2$ Hz, 2H, ArH), 4.06–4.00 and 3.99–3.90 (m, 1H, CHOH), 3.78 (s, 3H, OMe), 2.72–2.56 (m, 1H, H^4), 2.15–2.05 (m, 1H), 2.02–1.50 (m, 11H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.7, 141.5, 127.7, 113.9, 72.9, 71.8, 55.4, 46.4, 46.1, 38.4, 37.8, 37.3, 37.1, 37.0, 35.8, 31.9, 29.7, 23.4, 21.5 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 243.1358. $\text{C}_{14}\text{H}_{20}\text{O}_2\text{Na}$ requires 243.1356.

4.1.9. 4-(4-*t*-Butyldimethylsilyloxyphenyl)cycloheptanol 7b

The hydroboration/oxidation of **6b** (0.906 g, 2.99 mmol) with BH_3 -THF (1 [M](#) in THF, 6.0 mL, 6.0 mmol) was carried out in a fashion similar to the preparation of **7a**. Purification of the residue by column chromatography (SiO_2 , hexanes–ethyl acetate = 80:20) gave **7b** (0.880 g, 93%) as a yellow oil. This was determined to be a mixture of *cis*- and *trans*-stereoisomers by NMR spectroscopy. ^1H NMR (400 MHz, CDCl_3) δ 7.01 (m, 2H, ArH), 6.74 (m, 2H, ArH), 4.06–3.99 and 3.98–3.90 (m, 1H, CHOH), 2.69–2.53 (m, 1H, H^4), 2.14–1.49 (m, 11H), 0.97 (s, 9H, *t*-Bu), 0.18 (s, 6H, SiMe_2); ^{13}C NMR (100 MHz, CDCl_3) δ 153.6, 142.2, 142.1, 127.6, 119.9, 73.0, 71.9, 46.4, 46.1, 38.3, 37.8, 37.3, 37.1, 37.0, 35.9, 31.8, 29.8, 25.9, 23.5, 21.5, 18.4, –4.2 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 343.2064. $\text{C}_{19}\text{H}_{32}\text{O}_2\text{SiNa}$ requires 343.2064.

4.1.10. 4-(4-Methoxyphenyl)cycloheptanone ($\pm$)-8a

To a solution of **7a** (0.787 g, 3.58 mmol) in CH_2Cl_2 (38 mL) at room temperature, was added Dess–Martin periodinane (4.55 g, 10.7 mmol) and water (0.2 mL). The mixture was stirred at room temperature for 6 h, and then quenched with 50:50 sodium thiosulfate:sodium bicarbonate. The resulting solution was stirred at room temperature for 30 min and then extracted several times with ethyl acetate, dried (MgSO_4), and concentrated. The residue was purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 80:20) to give **8a** (0.389 g, 55%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.10 and 6.84 (AA'BB', $J_{\text{AB}} = 8.7$ Hz, 4H, ArH), 3.79 (s, 3H,

OMe), 2.77–2.53 (m, 4H), 2.16–1.52 (m, 7H); ^{13}C NMR (100 MHz, CDCl_3) δ 215.0, 157.9, 139.9, 127.4, 113.9, 55.3, 47.9, 43.8, 42.9, 38.6, 32.2, 23.8 ppm. The spectral data obtained for this compound were consistent with the literature values [16]. Oxidation of **7a** with either PCC/silica gel or *n*-propylmagnesium bromide/1,1'-(azodicarbonyl)dipiperidine gave **8a** (55% or 20% respectively).

4.1.11. 4-(4-*t*-Butyldimethylsilyloxyphenyl)cycloheptanone ($\pm$)-**8b**

The [oxidation](#) of **7b** (0.050 g, 0.16 mmol) with Dess–Martin periodinane (0.132 g, 0.312 mmol) and water (0.1 mL) was carried out in a fashion similar to the preparation of **8a**. Purification of the residue by column chromatography (SiO_2 , hexanes–ethyl acetate = 80:20) gave **8b** (0.036 g, 72%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.01 and 6.75 (AA'BB', J_{AB} = 8.6 Hz, 4H, ArH), 2.72–2.51 (m, 5H), 2.13–2.06 (m, 1H), 2.04–1.95 (m, 2H), 1.86–1.68 (m, 2H), 1.62–1.52 (m, 1H), 0.97 (s, 9H, *t*-Bu), 0.18 (s, 6H, SiMe_2); ^{13}C NMR (100 MHz, CDCl_3) δ 215.2, 154.0, 140.6, 127.5, 120.1, 48.1, 44.0, 43.1, 38.7, 32.3, 25.9, 24.0, 18.3, –4.2 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 341.1908. $\text{C}_{19}\text{H}_{30}\text{O}_2\text{SiNa}$ requires 341.1907.

4.1.12. Ethyl 5-(4-((*tert*-butyldimethylsilyl)oxy)phenyl)-2-oxocycloheptane-1-carboxylate ($\pm$)-**12**

To a solution of **11** (1.14 g, 3.74 mmol) in anhydrous ether (15 mL) at 0 °C under N_2 was added an aliquot of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (0.92 mL, 7.5 mmol), followed by the dropwise addition over a period of 20 min of a solution of ethyl diazoacetate (0.77 mL, 7.47 mmol) in anhydrous ether (5 mL). The reaction mixture was stirred at room temperature for 12 h, then cooled to 0 °C and neutralized with saturated aqueous NaHCO_3 . The mixture was extracted several times with CHCl_3 , and the combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated. The resultant dark yellow oil was purified by column chromatography (SiO_2 , hexanes–diethyl ether = 70:30) to give **12** (1.182 g, 81%) as a colorless oil. The product is a complex equilibrium mixture of two [diastereomeric](#) keto [tautomers](#) and one [enol](#) tautomer. ^1H NMR (400 MHz, CDCl_3) δ 12.74 (s, 0.4H, enol OH), 7.02–6.97 (m, 2H, ArH), 6.77–6.72 (m, 2H, ArH), 4.27–4.16 (m, 2H, OCH_2CH_3), 3.64 (t, J = 4.8 Hz) and 3.60 (dd, J = 12.0, 4.0 Hz, 0.3H total, $\text{O}=\text{CCHCO}_2\text{Et}$), 2.94–2.78 (m, 1H), 2.72–2.58 (m, 2H), 2.48–2.24 (m, 1H), 2.16–1.76 (m, 4H), 1.65–1.54 (m, 1H), 1.32 and 1.29 (2 x t, J = 7.2 Hz, 3H total, OCH_2CH_3), 0.97 (s, 9H, *t*-Bu), 0.18 (s, 6H, SiMe_2); ^{13}C NMR (100 MHz, CDCl_3) δ 209.0, 208.8, 178.9, 173.0, 170.6, 154.0, 140.9, 139.9, 127.7, 127.5, 120.2, 120.0, 101.5, 61.4, 60.7, 59.6, 58.5, 49.6, 47.9, 47.2, 42.2, 36.8, 35.4, 34.6, 32.8, 32.2, 27.8, 25.9, 23.9, 22.6, 18.4, 14.5, –4.2 ppm.

4.1.13. 4-(4-*t*-Butyldimethylsilyloxyphenyl)cycloheptanone ($\pm$)-**8b**

To a solution of **13** (0.205 g, 0.525 mmol) in DMSO (20 mL) at room temperature, was sequentially added [lithium chloride](#) (0.178 g, 4.20 mmol) and water (3.80 mL). The mixture was heated to 160 °C for 5 h, cooled to room temperature and poured into water. The resulting solution was extracted several times with ether and ethyl acetate. The combined extracts were washed with brine, dried (Na_2SO_4) and concentrated to give **8b** (0.122 g, 73%) as a colorless oil. The NMR spectral data for the product are consistent with that previously obtained.

4.1.14. 1-Methylene-4-(4-methoxyphenyl)cycloheptane ($\pm$)-**9a**

To a solution of methyltriphenylphosphonium bromide (1.25 g, 3.74 mmol) in anhydrous THF (30 mL) at –10 °C under N_2 , was added dropwise a solution of *n*-butyllithium (1.6 M in hexanes, 2.2 mL, 3.5 mmol). The deep yellow mixture was stirred for 45 min at –10 °C, followed by slow addition of a solution of **8a** (0.380 g, 1.74 mmol) in THF (10 mL). The solution changed from a deep to light yellow in color, and the mixture was gradually warmed to room temperature and stirred overnight. The solution was diluted with water, the layers separated and the aqueous layer was extracted several times with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO_4) and concentrated. The residue was purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 80:20) to give **9a** (0.296 g, 78%) as a light yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.10 and 6.83 (AA'BB', J_{AB} = 8.4 Hz, 4H, ArH), 4.77 (s, 2H, $\text{C}=\text{CH}_2$), 3.79 (s, 3H, OMe), 2.61–2.45 (m, 2H), 2.32

(broad t, $J = 12.2$ Hz, 2H), 2.00–1.84 (m, 3H), 1.71–1.48 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.7, 151.9, 141.7, 127.7, 113.8, 110.7, 55.4, 47.5, 38.0, 37.3, 36.2, 35.4, 27.5 ppm.

4.1.15. 4-(4-*t*-Butyldimethylsilyloxyphenyl)-1-methylenecyclohept-ane ($\pm$)-9b

The Wittig [olefination](#) of **8b** (0.212 g, 0.666 mmol) with the [ylide](#) generated from $\text{CH}_3\text{PPh}_3^+ \text{Br}^-$ (0.476 g, 1.33 mmol) and *n*-butyllithium (1.6 M in hexanes, 0.83 mL, 1.3 mmol) was carried out in a fashion similar to the preparation of **9a**. Purification of the residue by column chromatography (SiO_2 , hexanes–ethyl acetate = 90:10) gave **9b** (0.120 g, 57%) as a light yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.03 and 6.75 (AA'BB', $J_{\text{AB}} = 8.7$ Hz, 4H, ArH), 4.76 (s, 2H, $\text{C}=\text{CH}_2$), 2.59–2.45 (m, 2H), 2.37–2.26 (m, 2H), 2.01–1.85 (m, 3H), 1.70–1.48 (m, 4H), 1.00 (s, 9H, *t*-Bu), 0.20 (s, 6H, SiMe_2); ^{13}C NMR (100 MHz, CDCl_3) δ 153.6, 151.9, 142.3, 127.6, 119.9, 110.7, 47.6, 38.0, 37.2, 36.2, 35.4, 27.4, 25.9, 18.4, –4.2 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 339.2115. $\text{C}_{20}\text{H}_{32}\text{OSiNa}$ requires 339.2115.

4.1.16. 4-(4-Methoxyphenyl)cycloheptanemethanol 10a

To a solution of **9a** (0.296 g, 1.37 mmol) in freshly distilled THF (10 mL) at 0 °C, was added dropwise a solution of BH_3 -THF (1 M in THF, 2.7 mL, 2.7 mmol). The resulting mixture was warmed to room temperature and stirred for 20 h. The reaction mixture was cooled to 0 °C, and pure ethanol (115 mL) was slowly added followed by 30% H_2O_2 (2.0 mL) and 3 N NaOH (10 mL). The mixture was heated at reflux for 1 h, cooled to room temperature and extracted several times with ethyl acetate, the combined extracts were dried (MgSO_4), and concentrated. The residue was purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 60:40) to give **10a** (0.155 g, 48%) as a colorless gum. This was determined to be a mixture of *cis*- and *trans*-stereoisomers by NMR spectroscopy. ^1H NMR (400 MHz, CDCl_3) δ 7.11 and 6.83 (AA'BB', $J_{\text{AB}} = 8.8$ Hz, 4H, ArH), 3.77 (s, 3H, OMe), 3.46 (d, $J = 6.4$ Hz, 2H, CH_2OH), 2.69–2.55 (m, 1H), 2.00–1.72 (m, 8H), 1.68–1.39 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.6, 142.1, 141.8, 127.6, 113.8, 68.6, 68.3, 55.4, 47.2, 46.0, 42.2, 41.3, 38.8, 36.7, 36.4, 33.0, 31.5, 30.6, 29.9, 28.4, 27.5, 24.3 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 257.1515. $\text{C}_{15}\text{H}_{22}\text{O}_2\text{Na}$ requires 257.1512.

4.1.17. 4-(4-*t*-Butyldimethylsilyloxyphenyl)cycloheptanemethanol 10b

To a solution of **9b** (0.821 g, 2.71 mmol) in freshly distilled THF (10 mL) at 0 °C, was added dropwise a solution of borane-tetrahydrofuran [complex](#) (1 M in THF, 5.4 mL, 5.42 mmol). The resulting mixture was warmed to room temperature and stirred for 18 h. The reaction mixture was cooled to 0 °C, and 1 N [sodium hydroxide](#) (3.2 mL) was added slowly followed by 30% hydrogen peroxide (1.5 mL). The mixture was stirred for 1 h at room temperature, extracted several times with ethyl acetate, dried (Na_2SO_4), and concentrated. The residue was purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 80:20) to give **10b** (0.572 g, 66%) as a colorless oil. This was determined to be a mixture of *cis*- and *trans*-stereoisomers by NMR spectroscopy. ^1H NMR (400 MHz, CDCl_3) δ 7.02 and 6.74 (AA'BB', $J_{\text{AB}} = 8.3$ Hz, 4H, ArH), 3.45 (d, $J = 6.5$ Hz, 2H, CH_2OH), 2.67–2.53 (m, 1H), 1.98–1.38 (m, 11H), 1.29–1.09 (m, 1H), 0.98 (s, 9H, *t*-Bu), 0.19 (s, 6H, SiMe_2); ^{13}C NMR (100 MHz, CDCl_3) δ 153.5, 142.6, 127.6, 127.5, 119.9, 68.7, 68.5, 47.3, 46.1, 42.2, 41.3, 38.8, 36.7, 36.4, 33.1, 31.5, 30.7, 29.9, 28.5, 27.5, 25.9, 24.3, 18.4, –4.2 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 357.2218. $\text{C}_{20}\text{H}_{34}\text{O}_2\text{SiNa}$ requires 357.2220.

4.1.18. 4-(4-Hydroxyphenyl)cycloheptanemethanol ISP163

Method A: To a solution of **10a** (0.180 g, 0.769 mmol) in anhydrous CH_2Cl_2 (10 mL) at –78 °C, was added dropwise a solution of [boron](#) tribromide (1 M in CH_2Cl_2 , 2.31 mL, 2.31 mmol). The reaction mixture was stirred for 30 min at –78 °C and gradually warmed to room temperature over a 2 h period. The mixture was quenched with water (10 mL) and the layers separated. The aqueous layer was extracted several times with CH_2Cl_2 , and the combined organic extracts were washed with brine, dried (MgSO_4), and concentrated. Purification of the residue by column chromatography (SiO_2 , hexanes–ethyl acetate = 50:50) gave **ISP163** (0.048g, 30%) as a colorless solid. This product was determined to be a mixture of *cis*- and *trans*-stereoisomers NMR spectroscopy. mp 60–63 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.03 and 6.74 (AA'BB', $J_{\text{AB}} = 8.5$ Hz, 4H, ArH), 3.48 (d, $J = 6.6$ Hz, 2H, CH_2OH),

2.67–2.49 (m, 1H), 1.97–1.32 (m, 12H); ^{13}C NMR (100 MHz, CDCl_3) δ 153.7, 142.1, 127.9, 127.8, 115.3, 68.6, 68.6, 47.3, 46.0, 42.2, 41.3, 38.8, 36.6, 36.5, 33.0, 31.5, 30.6, 29.9, 28.5, 27.5, 24.3 ppm. Anal. Calcd. For $\text{C}_{14}\text{H}_{20}\text{O}_2$: C, 76.32; H, 9.15. Found: C, 76.21; H, 8.87.

Method B: To a solution of **10b** (0.873 g, 0.261 mmol) in anhydrous THF (20 mL) was added a solution of TBAF (1 M in THF, 10.0 mL, 0.010 mol). The mixture was heated to reflux at 70 °C overnight. After cooling to room temperature, the mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na_2SO_4) and concentrated. Purification of the residue by column chromatography (SiO_2 , hexanes–ethyl acetate = 60:40) gave **ISP163** (0.508 g, 88%) as a colorless solid. mp 60–63 °C. The ^1H NMR spectral data is consistent with that previously obtained.

ISP163P1: ^1H NMR (400 MHz, CDCl_3) δ 7.06 and 6.75 (AA'XX', $J_{\text{AX}} = 8.4$ Hz, 4H, ArH), 3.52–3.44 (m, 2H, CH_2OH), 2.63–2.54 (m, 1H), 1.97–1.32 (m, 12H); ^{13}C NMR (100 MHz, CDCl_3) δ 153.6, 142.0, 127.9, 115.3, 68.8, 47.3, 42.2, 36.8, 36.5, 30.6, 29.9, 24.3 ppm. HRMS (FAB): $\text{M}-\text{H}^+$, found 219.1390. $\text{C}_{14}\text{H}_{19}\text{O}_2$ requires 219.1391.

ISP163P3: ^1H NMR (400 MHz, CDCl_3) δ 7.05 and 6.75 (AA'XX', $J_{\text{AX}} = 8.4$ Hz, 4H, ArH), 3.48 (d, $J = 6.4$ Hz, 2H, CH_2OH), 2.67–2.59 (m, 1H), 1.97–1.40 (m, 12H); ^{13}C NMR (100 MHz, CDCl_3) δ 153.6, 142.2, 127.9, 115.3, 68.6, 46.0, 41.3, 38.8, 33.0, 31.5, 28.5, 27.5 ppm. HRMS (FAB): $\text{M}-\text{H}^+$, found 219.1391. $\text{C}_{14}\text{H}_{19}\text{O}_2$ requires 219.1391.

4.1.19. 4-(4-Hydroxyphenyl)cycloheptanone ($\pm$)-ISP242

A solution of **8a** (0.074 g, 0.339 mmol) in 48% HBr (8 mL) was heated at 115 °C for 2 h. The mixture was cooled to room temperature and partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous NaHCO_3 , followed by brine, dried (Na_2SO_4) and concentrated. The residue was purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 20:80) to give **ISP242** (0.057 g, 82%) as a brown syrup. ^1H NMR (400 MHz, CD_3OD) δ 6.98 and 6.70 (AA'BB', $J_{\text{AB}} = 8.5$ Hz, 4H, ArH), 4.98 (s, 1H, PhOH), 2.77–2.39 (m, 4H), 2.02–1.47 (m, 7H); ^{13}C NMR (100 MHz, CD_3OD) δ 218.1, 156.6, 140.4, 128.5, 116.2, 49.0, 44.7, 43.8, 39.8, 33.4, 24.8 ppm. HRMS (FAB): $\text{M} + \text{Na}^+$, found 227.1043. $\text{C}_{15}\text{H}_{22}\text{O}_2\text{Na}$ requires 227.1042.

4.1.20. 4-(4-Hydroxyphenyl)cycloheptanone oxime ($\pm$)-ISP166

To a solution of **ISP242** (0.048 g, 0.23 mmol) in ethanol (10 mL) was added NaHCO_3 (0.024 g, 0.29 mmol) and [hydroxylamine](#) hydrochloride (0.023 g, 0.69 mmol). The reaction was stirred at room temperature for 5 h and then extracted several times with ethyl acetate, and the combined extracts were dried (MgSO_4) and concentrated. The residue was purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 65:35) to give **ISP166** (26 mg, 50%) as a light brown syrup. This was determined to be a mixture of *E*- and *Z*-stereoisomers by NMR spectroscopy. ^1H NMR (400 MHz, CD_3OD) δ 6.98 and 6.67 (AA'BB', $J_{\text{AB}} = 8.5$ Hz, 4H, ArH), 2.86–2.30 (m, 4H), 2.09–1.20 (m, 8H); ^{13}C NMR (100 MHz, CD_3OD) δ 165.0, 164.8, 156.4, 156.3, 141.3, 140.4, 128.5, 128.3, 116.1, 40.0, 39.7, 37.1, 34.1, 33.7, 33.3, 29.6, 28.4, 27.9, 24.8 ppm. HRMS (FAB): $\text{M}_2 + \text{Na}^+$, found 457.2096. $(\text{C}_{13}\text{H}_{15}\text{NO}_2)_2\text{Na}$ requires 457.2098.

4.1.21. 4-(4-(2-Hydroxyethyl)cycloheptyl)phenol ($\pm$)-ISP248

Sodium [hydride](#) (32 mg, 55% in mineral oil, 0.809 mmol) was added to a stirring solution of trimethyl [phosphonoacetate](#) (0.130 mL, 0.809 mmol) in dry THF (3 mL) at 0 °C. After 45 min, a solution **8a** (0.147 g, 0.674 mmol) in dry THF (5 mL) was added and the reaction mixture was stirred at room temperature for 12 h. The mixture was diluted with water (15 mL) and the resulting mixture was extracted several times with ether, dried (MgSO_4) and concentrated. The residue was purified by column chromatography (SiO_2 , hexanes–ethyl acetate = 90:10) to give methyl 2-(4-(4-methoxyphenyl)cycloheptylidene)acetate (0.57 g, 30%) as a colorless oil. This compound was used in the next step without further characterization. To a solution of the previous compound (0.200 g, 0.730 mmol) in dry CH_2Cl_2 (5 mL) under nitrogen at –40 °C was added a solution of DIBAL (1.2 M in CH_2Cl_2 , 1.58 mL, 1.90 mmol). After stirring for 90 min, saturated aqueous potassium

sodium tartrate was added and reaction mixture was gradually warmed to room temperature. After 4 h the mixture was filtered through a pad of [celite](#) and extracted several times with water. The combined organic layers were dried (MgSO₄), and concentrated to give 4-(4-methoxyphenyl)-1-(2-hydroxyethyl)cycloheptane (0.078 g, 43%) as a colorless gum. The crude product was used in the next step without further purification. To a solution of the previous compound (0.078 g, 0.317 mmol) in [methanol](#) (10 mL) was added 10% Pd/C (0.040 g, 10 mol%). The mixture was stirred under balloon of H₂ at room temperature for 12 h. The reaction mixture was filtered through a pad of celite, concentrated and dried to give the crude product (0.080 g, 0.323 mmol). The crude product was dissolved in anhydrous CH₂Cl₂ (10 mL), cooled to –78 °C, and a solution of boron tribromide (1 M in CH₂Cl₂, 0.97 mL, 0.970 mmol) was added dropwise. After complete addition, the reaction mixture was stirred for 30 min at –78 °C and gradually warmed to room temperature over a 2 h period. The mixture was quenched with water and the mixture extracted several times with CH₂Cl₂. The combined organic extracts were washed with brine, dried (MgSO₄) and concentrated. The residue was purified by column chromatography (SiO₂, hexanes–ethyl acetate = 65:35) gave **ISP248** (0.005 g, < 10%) as a light brown solid. This was determined to be a mixture of *cis*- and *trans*-stereoisomers by NMR spectroscopy. ¹H NMR (400 MHz, CDCl₃) δ 7.04 and 6.74 (AA'BB', J_{AB} = 8.7 Hz, 4H, ArH), 3.71 (td, J = 6.9, 1.4 Hz, 2H, CH₂OH), 2.66–2.48 (m, 1H), 1.96–1.13 (m, 13H); ¹³C NMR (100 MHz, CDCl₃) δ 153.6, 142.2, 127.8, 115.3, 61.5, 47.1, 45.9, 41.1, 40.9, 38.8, 36.8, 36.3, 35.9, 35.4, 34.8, 34.5, 33.9, 33.0, 32.1, 27.3, 24.4 ppm.

4.1.22. 4-(4-Hydroxycycloheptyl)phenol (±)-ISP58

To a solution of **7a** (0.028 g, 0.14 mmol) in anhydrous CH₂Cl₂ (30 mL) at –78 °C, was added dropwise a solution of boron tribromide (1 M in CH₂Cl₂, 0.3 mL, 0.03 mmol). The resulting mixture was stirred at –78 °C for 30 min, then gradually warmed to room temperature over a 2 h period and quenched with water (10 mL). The mixture was extracted several times with CH₂Cl₂, the combined organic extracts were washed with brine, dried (MgSO₄) and concentrated to give **ISP58** (0.024 g, 86%) as a yellow [crystalline solid](#). This product was determined to be a mixture of *cis*- and *trans*-stereoisomers on the basis of NMR spectroscopy. ¹H NMR (400 MHz, CDCl₃) δ 7.11–6.99 (m, 2H, ArH), 6.80–6.70 (m, 2H, ArH), 4.85 (s, OH), 4.56–4.48 and 4.42–4.34 (m, 1H, RR'CHOH), 2.78–2.59 (m, 1H), 2.53–1.38 (m, 13H); ¹³C NMR (100 MHz, CDCl₃) δ 153.7, 141.1, 127.9, 115.4, 56.2, 55.8, 46.0, 45.5, 40.1, 39.6, 39.4, 38.0, 37.7, 36.5, 34.4, 31.4, 25.4, 23.7 ppm.

4.1.23. 4-(6-Oxabicyclo[3.2.2]nonan-5-yl)phenol (±)-ISP360

To a solution of **ISP163** (0.075 g, 0.340 mmol) in anhydrous CH₂Cl₂ (20 mL) at –10 °C, was slowly added a suspension of DDQ (77 mg, 0.34 mmol) in CH₂Cl₂ (5 mL) over a period of 30. The green solution was stirred at 0 °C for 2 h, and at room temperature for an additional 3 h. The mixture was quenched by slow addition of saturated sodium bicarbonate solution at 0 °C, the layers were separated and aqueous layer was extracted several times with CH₂Cl₂. The combined organic extracts were washed with brine, dried (Na₂SO₄), and concentrated. Purification of the residue by column chromatography (SiO₂, hexanes–ethyl acetate = 60:40) gave product **ISP360** (0.049 g, 66%) as a light yellow viscous oil. ¹H NMR (400 MHz, CDCl₃) δ 7.15 and 6.58 (AA'BB', J_{AB} = 7.8 Hz, 4H, ArH), 6.30 (s, 1H, PhOH), 4.07–3.96 (m, 1H), 3.90–3.84 (m, 1H), 2.25–1.60 (m, 11H); ¹³C NMR (100 MHz, CDCl₃) δ 154.3, 142.4, 125.7, 115.0, 76.6, 69.9, 42.9, 33.8, 32.5, 30.3, 22.5, 21.4 ppm. HRMS (FAB): M₂ + Na⁺, found 457.2346. (C₁₄H₁₈O₂)₂Na requires 457.2349.

4.2. Determining ISP163 extinction coefficient and isomer stock concentrations

Stocks of compounds dissolved in DMSO were stored at –20 °C as aliquots to reduce the number of [freeze-thaw](#) cycles. Stocks were diluted in 20 mM [potassium phosphate](#) buffer, pH 7.5 and DMSO was kept at 0.4%. The absorbance of [dilutions](#) was scanned from 200 to 400 nm in a GENESY™ 10S [UV-Vis](#) spectrophotometer (Thermo Fisher Scientific) set at medium speed with a 1 nm interval. A buffer blank with 0.4% DMSO was also read. The absorbance peak at 276 nm was plotted against concentration and a linear regression with the line forced through 0,0 was fit to the data. The average of 3 replicates was calculated to be the extinction coefficient

of **ISP163**. Absorbance scans of dilutions of **ISP163 isomers** stocks in the same buffer with 0.4% DMSO were scanned. The extinction coefficient of $1892\text{ M}^{-1}\text{cm}^{-1}$ was used to calculate the concentration of **ISP163** isomers stock solutions.

4.3. Biological evaluation

4.3.1. TR-FRET ligand binding displacement assay

To determine the ability of compounds to bind to ER β or ER α , the Lanthascreen® TR-FRET [Competitive Binding](#) assay kit (Thermo Fisher Scientific) was used. In this assay, the ER β or ER α [ligand-binding domain](#) (LBD) was tagged with GST, and anti-GST antibody was tagged with [terbium](#), and [estrogen](#) was tagged with [fluorescein](#). The assay was set up in a 384-well low volume white plate (Corning® 4512), and incubated for 1 h at room temperature. After incubation, the plate was spun at 1000 rpm for 1 min in a centrifuge with swing-out rotor (Eppendorf 5810, rotor A-4-64). Then the plate was read according to Thermo Fisher Scientific settings (excitation at 332 nm, [emission wavelengths](#) of 518 nm and 488 nm with 420 nm cutoff, 50 μs integration delay, 400 μs integration time, and 100 flashes per read) in a SpectraMax M5 plate reader (Molecular Devices). The TR-FRET ratio of fluorescein (518 nm) over terbium (488 nm) emission was calculated by SoftMax Pro 6.2.2 (Molecular Devices). Data were analyzed using [Prism 6](#) (GraphPad). Data were normalized to the TR-FRET ratio of 1% DMSO (negative) and 1 μM E2 (positive) controls and EC₅₀ values were calculated by doing a nonlinear square fit of the data with the high concentrations of competing ligand constrained to zero. Standard deviations for the nonlinear least squares fit are reported. For replicate assays, the EC₅₀ for curves that gave the median value are reported in [Table 1](#).

4.3.2. TR-FRET Coactivator Binding Assay

To determine the ability of **ISP163p4** to direct the correct conformational change to recruit coactivator proteins, the Lanthascreen® TR-FRET Coactivator Assay (Thermo Fisher Scientific) was used. The assay was conducted using the Thermo Fisher Scientific's SelectScreen™ services. Similar to the binding assay, a GST-tagged ER β or ER α –LBD and Terbium-labeled anti-GST antibody were used. In this assay, once an [agonist](#) compound binds the ER-LBD, the LBD undergoes a conformational change and a fluorescein-tagged peptide derived from PPAR λ is recruited. The TR-FRET ratio of the emission of fluorescein over Terbium was calculated and data were normalized to 1% DMSO and E2 controls (E2 EC₅₀ was 2.58 nM for ER α and 3.43 nM for ER β in this assay). EC₅₀ values were calculated by doing nonlinear squares fits of the data using Prism 6 (GraphPad). Reported standard deviations are for the fit.

4.3.3. Cellular FRET-based GeneBLAzer™ assays

Selectivity measurements for **ISP163p4** were performed using the SelectScreen™ cell-based [nuclear receptor](#) profiling service from ThermoFisher. Nuclear receptors (NR) to be screened in the specificity assay were selected based on two main criteria: (a) sequence and structural similarity to estrogen receptor and (b) availability of the assay. When choosing between possible isoforms, we chose those that were more likely to be involved in CNS function. The 9 NHRs tested were [Androgen Receptor](#) (AR), Glucocorticoid Receptor (GR), [Mineralocorticoid Receptor](#) (MR), [Peroxisome Proliferator-Activated Receptor](#) (PPAR δ), [Progesterone Receptor](#) (PR), [Thyroid Hormone Receptor](#) (TR β), and Vitamin D Receptor (VDR), ER β , and ER α . This is a FRET-based assay that uses GeneBLAzer™ technology. It detects [ligand binding](#) to and activation of [nuclear hormone receptor](#) of interest (ligand binding domain; LBD) that is fused to the DNA-binding Domain (DBD) of GAL4. Upon appropriate ligand binding, the GAL4 DBD binds the upstream activator sequence and transcription of the [beta-lactamase](#) cDNA results. Cells are loaded with a beta-lactamase substrate containing fluorescein and [coumarin](#) such that cells fluoresced green when beta-lactamase was absent. When beta-lactamase was present, the substrate was cleaved and the cells fluoresced blue. The ratio of coumarin to fluorescein emission was calculated then normalized to negative and positive controls ([Table 3](#)). Compound stocks were in DMSO and

diluted for assay concentrations of 25, 2.5, and 0.25 μM . Assays for ER α and ER β were repeated in a 10-point dose response curve and data was normalized as stated previously. The E2 positive control EC₅₀ values were 0.151 nM and 0.568 nM for ER α and ER β , respectively.

Table 3. [Nuclear hormone receptor](#) specificity assay positive controls and IC₅₀ values.

Control Compound	IC ₅₀ (nM)	Nuclear Hormone Receptor
R1881	0.302	Androgen Receptor (AR)
17 β -estradiol (E2)	0.107, 0.579	Estrogen Receptor (ER α , ER β)
Dexamethasone	2.35	Glucocorticoid Receptor (GR)
Aldosterone	0.305	Mineralocorticoid Receptor (MR)
L-165041	12.6	Peroxisome Proliferator-Activated Receptor (PPAR δ)
R5020	0.236	Progesterone Receptor (PR)
T3 Free Acid	0.103	Thyroid Hormone Receptor (TR β)
Calcitriol	0.0953	Vitamin D Receptor (VDR)

4.3.4. Cell-based agonist and antagonist assays

Kits from INDIGO Biosciences were used to examine the impact of compounds on agonist and [antagonist](#) activity for full-length, native ER β and ER α . In this assay, a [luciferase reporter gene](#) was downstream from an ER-responsive promoter activated by an agonist. Antagonist assays tested if compound could block activation by E2 while agonist assays tested if compound could activate transcription. [Chemiluminescence](#) resulting from ER-induced luciferase expression was measured in a SpectraMax M5 (Molecular Devices). Stock solutions in DMSO were diluted to final concentrations (low μM to nM) in compound screening media such that DMSO was kept below 0.4%. Vehicle and E2 controls were included in each assay. E2 had agonist activity IC₅₀ values of 0.31 ± 0.03 nM and 0.022 ± 0.005 nM for ER α and ER β , respectively. Kit instructions were followed. Briefly, cells were taken directly from the freezer and cell recovery media was added. Cells were incubated at 37 °C for 5 min. Half the cells were plated for agonist assays, while the other half had E2 added and were then plated for antagonist assays. Compound dilutions were then added to plated cells and the plate was incubated at 37 °C with 5% CO₂ for 22–24 h. Media was removed and detection reagent was added before [luminescence](#) was read. Data were normalized to controls and EC₅₀ values were calculated by doing a nonlinear squares fit using Prism 6 (GraphPad). Standard deviations are for the nonlinear fit.

4.3.5. Psychoactive Drug Screening Program (PDSP)

A solid sample of **ISP163** was sent to Brian Roth at the University of North Carolina at Chapel Hill for screening by the NIMH PDSP using published methods [24].

4.3.6. ER β docking studies

All ligands were prepared in three dimensional (3D) conformations with proper [stereochemistry](#). Ligand files were prepared for docking using [AutoDock](#) Tools (ADT) [22], version 1.5.6, and Gasteiger charges were assigned. The ER β receptor in the agonist conformation (pdb code 2jj3) [19] was also prepared for docking calculations, using ADT to add partial charges and [hydrogens](#). The grid box was centered on the co-crystallized ligand, including ER β active site residues Arg346, Glu305, and His475. Docking was performed using AutoDock Vina [21] with default parameters, except an exhaustiveness of 8 and energy range of 4 was used.

4.3.7. Cytochrome P450 assays

[Metabolism](#) of compounds by [cytochrome P450](#) enzymes was assessed using Promega P450-Glo™ Screening Systems (Madison, WI) for [CYP2D6](#), 3A4, 1A2, and 2C9. Compound stocks were maintained in DMSO and diluted into the assay such that DMSO was kept at 0.25%. In this assay, the relevant CYP450 enzyme metabolizes a pro-luciferin substrate. A secondary luciferase reaction produces light proportional to the amount

of [luciferin](#) product generated. Compounds that inhibit CYP450 enzyme action show reduced light production. Assays were run according to kit instructions. Briefly, compound dilutions and a mix of the relevant CYP450 enzyme with pro-luciferin substrate was added to a white 96-well plate (Corning® 3912) and incubated at 37 °C for 10 min. The CYP450 [enzyme reaction](#) was initiated by the addition of a [NADPH](#) regeneration system and the reaction was incubated at 37 °C for 10–30 min. The CYP450 enzyme reaction was stopped by the addition of the luciferin detection reagent, which initiated the luciferase reaction. Chemiluninescence was read on a SpectraMax M5 (Molecular Devices) after incubating the plate for 20 min at room temperature. Data were normalized to vehicle controls and nonlinear square fits of the data were conducted using Prism 6 (GraphPad). Positive controls (quinidine for CYP2D6, [ketoconazole](#) for [CYP3A4](#), [α-naphthoflavone](#) for [CYP1A2](#), and sulfaphenazole for CYP2C9) were also included on each assay plate.

4.3.8. Nephelometry

[Nephelometry](#) measures the relative [light scattering](#) of molecular aggregates and was used to measure the likelihood of compound [solubility](#) in assays. Molecular aggregates in solutions cause artificial assay results, thus it is important to assess compound aggregation in solution. Compounds were tested for aggregation in clear 96-well plates (Greiner Bio-One). Compounds were dissolved in 0.45 µm-filtered buffer containing 20 mM potassium phosphate pH 7.5 and 1% DMSO. Dilutions of [progesterone](#) were included as positive controls in each assay. Buffer-only controls were used to blank the NEPHELOstar (BMG LABTECH), which was equipped with a 635 nm laser. The gain was set to 90. Compound was considered soluble if it had a nephelometry inflection point greater than 50 µM [23].

4.3.9. Breast cancer proliferation assays

The impact of **ISP163** on the growth of human breast cancer cells was tested in [MTT assays](#). MCF-7 cells were kindly provided by Dr. Manish Patankar (University of Wisconsin-Madison) and cultured in Eagle's Minimum Essential Media (EMEM) supplemented with 10% fetal [bovine](#) serum and 0.01 mg/mL human recombinant [insulin](#) in an incubator maintained at 37 °C and 5% CO₂. Cells were seeded into a 96-well plate at 7000 cells per well and incubated for 24 h after which media was aspirated and treatment dissolved in EMEM was applied. All wells contained 0.1% DMSO, except for dead (negative) controls which contained 100% DMSO. Positive controls contained 0.01 µM E2. **ISP163** was tested at 10-fold dilutions ranging from 10 to 0.001 µM. After a second 24 h incubation, the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay was performed by adding 20% MTT in EMEM to each well and incubating an additional 4 h. [Formazan](#) crystal metabolites were dissolved with 100% DMSO and absorbance was read at 570 nm and 650 nm using a [Vmax](#) plate reader (Molecular Devices) running SoftmaxPro v 6.1. A standard growth curve was used to convert absorbance units to cell number. Two-sample equal variance t-tests were conducted in Microsoft Excel to determine if [cell proliferation](#) was significantly different from untreated controls or wells treated with E2.

Acknowledgments

This work was supported in part by grant [R15GM118304](#) from the National Institute of General Medical Sciences. [High-resolution mass spectra](#) were obtained at the Old Dominion University COSMIC facility. We thank Adam J. Wargolet and Rochelle M. Van Hart for their expert help running the [MTT assays](#). CNS receptor and hERG [percent inhibition](#) was generously provided by the National Institute of [Mental Health's](#) Psychoactive [Drug Screening](#) Program, Contract # HHSN-271-2013-00017-C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD, USA.

Appendix A. Supplementary data

Download : [Download Acrobat PDF file \(1MB\)](#)

Research data for this article

Cambridge Crystallographic Data Center

Crystallographic data

Data associated with the article:

[CCDC 1846634: Experimental Crystal Structure Determination](#)

[CCDC 1846643: Experimental Crystal Structure Determination](#)

[CCDC 1846646: Experimental Crystal Structure Determination](#)

References

- [1] A. Chhibber, S.K. Woody, M.A.K. Rumi, M.J. Soares, L. Zhao **Estrogen receptor β deficiency impairs BDNF-5-HT_{2A} signaling in the hippocampus of femal brain: a possible mechanism for menopausal depression** Psychoneuroendocrinology, 82 (2017), pp. 107-116
- [2] H.R. Sharma, M.K. Thakur **Correlation of ER α /ER β expression with dendritic and behavioural changes in CUMS mice** Physiol. Behav., 145 (2015), pp. 71-83
- [3] (a) Z. Tian, J. Fan, Y. Zhao, S. Bi, L. Si, Q. Liu **Estrogen receptor beta treats Alzheimer's disease** Neural Regen. Res., 8 (2013), pp. 420-426 (b) S. George, G.H. Petit, G.K. Gouras, P. Brundin, R. Olsson **Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid- β levels in a mouse model of Alzheimers's disease** ACS Chem. Neurosci., 4 (2013), pp. 1537-1548 (c) F. Liu, M. Day, L.C. Muniz, D. Bitran, R. Arias, R. Rivilla-Sanchez, S. Grauer, G. Zhang, C. Kelley, V. Pulito, A. Sung, R.R. Mervis, R. Navarra, W.D. Hirst, P.H. Reinhart, K.L. Marquis, S.J. Moss, M.N. Pangalos, N.J. Brandon **Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory** Nat. Neurosci., 11 (2008), pp. 334-343
- [4] (a) G. Pinton, S. Nilsson, L. Moro **Targeting estrogen receptor beta (ER β) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ER β expression and functionality** Oncogenesis, 7 (2018), p. 15 (b) G.R. Sareddy, B.C. Nair, V.K. Gonugunta, Q.G. Zhang, A. Brenner, D.W. Brann, R.R. Tekmal, R.K. Vadlamudi **Therapeutic significance of estrogen receptor β agonists in gliomas** Mol. Canc. Therapeut., 11 (2012), pp. 1174-1182
- [5] (a) A. Rani, M. Kaur, A. Bansal, P. Kaur, M. Kumari, J. Kumari, R.K. Gill, J. Bariwal **A walk around clinically used selective estrogen receptor modulators (SERMs) in breast cancer management** Chem. Biol. Interface, 3 (2013), pp. 83-94 (b) V. Beral **Breast cancer and hormone-replacement therapy in the million women study** Lancet, 362 (2003), pp. 419-427 (c) C.I. Li, K.E. Malone, P.L. Porter, N.S. Weiss, M.T. Tang, K.L. Cushing-Haugen, J.R. Daling **Relationship between long durations and different regimens of hormone therapy and risk of breast cancer** J. Am. Med. Assoc., 289 (2003), pp. 3254-3263
- [6] (a) K. Ohta, T. Ogawa, A. Oda, A. Kaise, Y. Endo **Design and synthesis of carborane-containing estrogen receptor-beta (ER β)-selective ligands** Bioorg. Med. Chem. Lett, 25 (2015), pp. 4174-4178 (b) F. Minutolo, M. Macchia, B.S. Katzenellenbogen, J.A. Katzenellenbogen **Estrogen receptor β ligands: recent advances and biomedical applications** Med. Res. Rev., 31 (2011), pp. 364-442 (c) S. Bertini, A. De Cupretinis, C. Granchi, B. Bargagli, T. Tuccinardi, A. Martinelli, M. Macchia, J.R. Gunther, K.E. Carlson, J.A. Katzenellenbogen, F. Minutolu **Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicyladoximes** Eur. J. Med. Chem., 46 (2011) 2543-2462 (d)

E.S. Manas, R.J. Unwalla, Z.B. Xu, M.S. Malamas, C.P. Miller, H.A. Harris, C. Hsiao, T. Akopaian, W.T. Hum, K. Malakian, S. Wolfrom, A. Bapat, R.A. Bhat, M.L. Stahl, W.S. Somers, J.C. Alvarez **Structure-based design of estrogen receptor- β selective ligands** J. Am. Chem. Soc., 126 (2004), pp. 15106-15119

[7]

S. Nilsson, S. Makela, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, J. Gustafsson **Mechanisms of estrogen action** Physiol. Rev., 81 (2001), pp. 1535-1565

[8]

A.C.W. Pike, A.M. Brzozowski, R.E. Hubbard, T. Bonn, A.G. Thorsell, O. Engstrom, J.K. Ljunggren, J.A. Gustafsson, M. Carlquist **Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist** EMBO J., 18 (1999), pp. 4608-4618

[9]

M.S. Malamas, E.S. Manas, R.E. McDevitt, I. Gunawan, Z.B. Xu, M.D. Collini, C.P. Miller, T. Dinh, R.A. Henderson, J.C. Keith Jr., H.A. Harris **Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor- β ligands** J. Med. Chem., 47 (2004), pp. 5021-5040

[10]

B.H. Norman, J.A. Dodge, T.I. Richardson, P.S. Borromeo, C.W. Lugar, S.A. Jones, K. Chen, Y. Wang, G.L. Durst, R.J. Barr, C. Montrose-Rafizadeh, H.E. Osborne, R.M. Amos, S. Guo, A. Boodhoo, V. Krishnan **Benzopyrans are selective estrogen receptor β agonists with novel activity in models of benign prostatic hyperplasia** J. Med. Chem., 49 (2006), pp. 6155-6157

[11] M.J. Weiser, T.J. Wu, R.J. Handa **Estrogen receptor- β agonist diarylpropionitrile: biological activities of R- and S-Enantiomers on behavior and hormonal response to stress** Neuroendocrinology, 150 (2009), pp. 1817-1825

[12] V.M. Carroll, M. Jeyakumar, K.E. Carlson, J.A. Katzenellenbogen **Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β -selective ligands** J. Med. Chem., 55 (2011), pp. 528-537

[13] J.S. Wright, H. Shadnia, J.M. Anderson, T. Durst, M. Asim, M. El-Salifiti, C. Choueiri, M.A. Pratt, S.C. Ruddy, R. Lau, K.E. Carlson, J.A. Katzenellenbogen, P.J. O'Brien, L. Wan **A-CD estrogens. I. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds** J. Med. Chem., 54 (2011), pp. 433-448

[14]

C. McCullough, T.S. Neumann, J.R. Gone, Z. He, C. Herrild, J. Wondergem, R.K. Pandey, W.A. Donaldson, D. S. Sem **Probing the human estrogen receptor- α binding requirement for phenolic mono- and di-hydroxyl compounds: a combined synthesis, binding and docking study** Bioorg. Med. Chem., 22 (2014), pp. 303-310

[15] C. Tao, W.A. Donaldson **Reactivity of tricarbonyl(pentadienyl)-iron(1+) cations: enantioselective synthesis of 5-HETE methyl ester** J. Org. Chem., 58 (1993), pp. 2134-2143

[16] T. Hashimoto, S. Isobe, C.K.A. Callens, K. Maruoka **Axially chiral dicarboxylic acid catalyzed asymmetric semipinacol rearrangement of cyclic β -hydroxy- α -diazo esters** Tetrahedron, 68 (2012), pp. 7630-7635

[17] CCDC 1846634 (ISP163p2), 1846646 (ISP163p3), 1846643 (ISP163p4) contain the supplementary crystallographic data for this paper. These data are provided free of charge by The Cambridge Crystallographic Data Centre.

[18] We Thank One of the Reviewers for Suggesting This Possibility.

[19]

A.K. Shiau, D. Barstad, J.T. Radek, M.J. Meyers, K.W. Nettles, B.S. Katzenellenbogen, J.A. Katzenellenbogen, D.A. Agard, G.L. Greene **Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism** Nat. Struct. Biol., 9 (2002), pp. 359-364

[20] K. Wang, F. Li, L. Chen, Y.M. Lai, X. Zhang, H.Y. Li **Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose response meta-analysis of prospective studies** Oncotarget, 8 (2017), pp. 81109-81124

[21] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson **AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility** J. Comput. Chem., 30 (2009), pp. 2785-2791

[22] C.N. Cavasotto, A.J. Orry **Ligand docking and structure-based virtual screening in drug discovery** Curr. Top. Med. Chem., 7 (2007), pp. 1006-1014

[23] K.A. Dehring, H.L. Workman, K.D. Miller, A. Mandagere, S.K. Poole **Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility** J. Pharmaceut. Biomed. Anal., 36 (3) (2004), pp. 447-456

[24]

J. Besnard, G.F. Ruda, V. Setola, K. Abecassis, R.M. Rodriguiz, X.P. Huang, S. Norval, M.F. Sassano, A.I. Shin, L.A. Webster, F.R. Simeons, L. Stojanovski, A. Prat, N.G. Seidah, D.B. Constam, G.R. Bickerton, K.D. Read, W.C. Wetsel, Gilbert, I.H.B.L. Roth, A.L. Hopkins **Automated design of ligands to polypharmacological profiles** Nature, 492 (2012), pp. 215-220